Josh Bilenker’s team at Eli Lilly chops 3 cancer drug programs in pipeline cleanup as their $1.6B IL-10 effort flames out
Eli Lilly cut 3 early and mid-stage cancer drug programs from the pipeline today, 3 weeks after the new oncology team under Josh Bilenker nixed an alliance it had underway in the field with NextCure.
I’m still lining up the drugs with the program, but the targets make for an interesting list.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.